Corcept Therapeutics | CORT - Operating Expenses


Corcept Therapeutics reported $214.85M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Alaunos Therapeutics USD 1.01M 175K Mar/2026
ANI Pharmaceuticals USD 597.21M 34.91M Jun/2026
Ardelyx USD 127.27M 7.15M Mar/2026
Aurora Cannabis CAD 48.04M 81.94M Mar/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Canopy Growth CAD 98.72M 11.51M Mar/2026
Corcept Therapeutics USD 214.85M 343K Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
J&J USD 17.83B 388M Jun/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Merck USD 15.77B 2.4B Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novartis USD 10.2B 912M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 180.54M 7.79M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026